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The “linked evidence approach” to
assess medical tests: A critical analysis
Tracy Merlin, Samuel Lehman
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Janet E. Hiller
Faculty of Health Sciences, Australian Catholic University
Philip Ryan
Data Management & Analysis Centre (DMAC), Discipline of Public Health, School of Population
Health, University of Adelaide
Objectives: A linked evidence approach (LEA) is the synthesis of systematically acquired evidence on the accuracy of a medical test, its impact on clinical decision making and the
effectiveness of consequent treatment options. We aimed to assess the practical utility of this methodology and to develop a decision framework to guide its use.
Methods: As Australia has lengthy experience with LEA, we reviewed health technology assessment (HTA) reports informing reimbursement decisions by the Medical Services
Advisory Committee (August 2005 to March 2012). Eligibility was determined according to predetermined criteria and data were extracted on test characteristics, evaluation
methodologies, and reported difficulties. Fifty percent of the evidence-base was independently analyzed by a second reviewer.
Results: Evaluations of medical tests for diagnostic (62 percent), staging (27 percent), and screening (6 percent) purposes were available for eighty-nine different clinical
indications. Ninety-six percent of the evaluations used either the full LEA methodology or an abridged version (where evidence is linked through to management changes but not
patient outcomes). Sixty-one percent had the full evidence linkage. Twenty-five percent of test evaluations were considered problematic; all involving LEA (n = 22). Problems
included: determining test accuracy with an imperfect reference standard (41 percent); assessing likely treatment effectiveness in test positive patients when the new test is more
accurate than the comparator (18 percent); and determining probable health benefits in those symptomatic patients ruled out using the test (13 percent). A decision framework was
formulated to address these problems.
Conclusions: LEA is useful for evaluating medical tests but a stepped approach should be followed to determine what evidence is required for the synthesis.
Keywords: Diagnostic test approval, Evaluation methodology, Systematic review, Reimbursement mechanisms
Guidance on the assessment of medical tests has been pro-
duced only recently (2008–11) in the United States (1–3) and
Europe (4), including an interim methods guide from England
(5). Australia developed its own guidance for the assessment of
medical tests for reimbursement purposes in 2005 (6;7), propos-
ing a “linked evidence approach,” which has subsequently
been recommended in each of these international guidance
documents.
A recent review (8) of 149 English-language health technol-
ogy assessments (HTAs) of medical tests, conducted by eigh-
teen agencies in eight countries, indicated that the majority of
HTAs using LEA follow the Australian evaluation framework.
As policies regarding public funding are dependent on the qual-
ity and quantity of information provided to the decision maker,
it is timely to reflect on the lessons learned from the application
of LEA.
What Is the Linked Evidence Approach (LEA) and When Is It Used?
LEA methodology in Australia (6;7) was based on analytic
frameworks used by the United States Preventive Services Task
Thanks to Dr Sarah Lord for permission to reproduce Figure 1; and to Ms Skye Newton for her
comments on the draft before submission. Source of funding: Nil.
Force (USPSTF) in the development of clinical practice guide-
lines (9), as well as criteria developed by Fryback and Thorn-
bury (1991) to assess the efficacy of diagnostic imaging tests
(10). Fryback and Thornbury’s efficacy criteria includes techni-
cal efficacy, diagnostic accuracy, diagnostic thinking (change in
diagnosis), therapeutic efficacy (change in management), and
patient outcome efficacy (change in health outcomes). “Out-
come efficacy” or clinical effectiveness is the factor that is of
the greatest relevance to policy makers for public funding de-
cisions, and to clinicians determining the best use of testing in
managing their patients.
The paramount method of determining the clinical effec-
tiveness of a test is through the direct impact of the test on patient
health outcomes. This is, ideally, a randomized controlled trial
whereby patients are randomized to assessment with or without
use of the medical test and, subsequent to treatment, their health
outcomes are measured. However, this type of direct evidence
is often lacking (11).
DiRuffano et al. noted this lack, stating “policy and decision
makers frequently need to resort to lower grade evidence, such
as decision models to provide guidance on test selection and
use” (11). The Australian, and more recent U.S. and European,
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Figure 1. The use of direct evidence compared with linked evidence in the evaluation of diagnostic tests in a health technology assessment framework. Source: Lord S, Ghersi D, Simes J, Irwig L. (2005) Medical Services
Advisory Committee: Guidelines for the assessment of diagnostic technologies. Canberra: Commonwealth of Australia. Reproduced with permission.
The Australian Medical Services Advisory Committee
(MSAC) guidelines recommend the systematic review and nar-
rative linking of key aspects of Fryback and Thornbury’s effi-
cacy criteria, under certain conditions. This linking of evidence
would occur in instances where direct trial evidence of the clin-
ical effectiveness of a test is not available, or is inadequate for
decision making purposes (6). In some cases, evidence of test
accuracy would be considered a sufficient proxy for diagnostic
effectiveness if there is reasonable justification to assume that
the population receiving the new test is to all intents and pur-
poses the same population that would receive treatment for the
condition—and there is good evidence that treatment impacts
positively on the health outcomes in this population. This is the
transferability assumption (see Figure 1).
Transferability cannot be assumed if a positive result using
the new test leads to earlier, new or alternative treatments that
have not been evaluated in clinical trials. If the new test results
in additional cases being detected, and thus the spectrum of
disease in the diagnosed population changes, then evidence of
treatment effectiveness in this broader population (bymeans of a
systematic review of treatment effectiveness) would be needed.
If these data are unavailable, then a linked evidence approach is
not informative (6).
OBJECTIVE
The aim of this study was to determine whether LEA is feasible
and to identify situations where its use may be problematic for
informing reimbursement decisions. The objective was to use
the findings from this study to inform the development of a
decision framework for applying LEA.
METHODS
HTA reports commissioned by MSAC, and conducted by pre-
dominantly independent academic evaluation groups, were in-
cluded in the analysis if they met the following criteria: (i) Con-
sidered by MSAC between August 2005 and March 2012; (ii)
Publicly available on the MSAC Web site (www.msac.gov.au)
between February and March 2012; (iii) A test requested for
reimbursement through government referral, industry applica-
tion, or an update of a previous assessment; and (iv) A test used
for diagnostic, screening or staging purposes.
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Diagnostic tests were considered to identify new patholog-
ical conditions in symptomatic patients; screening tests were
considered to identify new pathological conditions in asymp-
tomatic or apparently healthy persons; and staging tests were
considered to characterize the stage of disease in a patient pre-
viously diagnosed. Diagnostic tests that may have a therapeutic
component were included, for example, a biopsy that happened
to capture all of the diseased tissue and so effectively treated
the condition.
HTAswere excluded in the following circumstances: (i) The
test being assessed was used for monitoring a specific treatment
eg titrating a drug according to a biomarker concentration; (ii)
The test being assessed was pharmacogenetic, that is, part of
a co-dependent technology pairing (12); or (iii) The HTA was
commercial in confidence, withdrawn or not produced.
Monitoring and pharmacogenetic tests were excluded be-
cause the relationship with a single (usually drug) treatment is
closer, thus the likelihood of direct evidence being available is
higher than with diagnostic, staging or screening tests.
All agencies commissioned to undertake evaluations of
medical tests for MSAC were required to follow the MSAC
diagnostic guidelines following their implementation in 2005
(6).
Independent duplicate selection and data extraction oc-
curred for 50 percent of all identified HTAs. The unit of analysis
was test evaluation per clinical indication, as tests were often
used for multiple purposes and thus several evaluations may
have been included in one HTA report. Data were extracted
and coded for the following variables: report details, author,
test type (high sensitivity and specificity, rule in, rule out, not
enough information, other) and purpose (triage, replacement,
add-on), the target population for the test (clinical indications),
year ofMSAC consideration, the comparator test, identified ref-
erence standard to determine test accuracy, quality of reference
standard (as discussed in the report), methodological approach,
and methodological issues encountered (problems with LEA as
discussed in the report).
Methodological approachwas coded as: (i) “direct evidence
only” - reporting only on direct clinical trials, from test to mea-
surement of patient health outcomes; (ii) “direct evidence plus
full LEA” - reporting on direct clinical trials and supplementing
this with a linkage of evidence on the accuracy of the medical
test, its impact on clinical decision-making (e.g., changes in
patient management), and the effectiveness of consequent treat-
ment options; (iii) “direct evidence plus LEA but full linkage
not required” - reporting on direct clinical trials and supple-
menting this with an abridged LEA. An abridged LEA would
search for evidence on the accuracy of the medical test and
of its impact on clinical decision-making, but would not then
assess the effectiveness of consequent treatment options due to
the treatment being well established and the patient spectrum
of disease being similar to those patients currently receiving
treatment; (iv) “components of LEA” - reporting on isolated
aspects of the test effectiveness pathway (most commonly, test
accuracy alone) with no rationale given for selecting only those
components; (v) “direct evidence plus components of LEA” -
reporting on direct clinical trials and supplementing this with
reporting on isolated aspects of the test effectiveness pathway
(most commonly, test accuracy alone) with no rationale given
for selecting only those components.
Tests were characterized as having high sensitivity and
specificity if, relative to an appropriate reference standard, both
parameters were 85 percent or higher. “Rule in” tests were de-
fined as having high positive predictive value (as reported by
the authors), or in the absence of prevalence data, high speci-
ficity. “Rule out” tests were defined as having high negative
predictive value (as reported by the authors), or in the absence
of prevalence data, high sensitivity. Descriptive statistics were
calculated and results were analyzed qualitatively.
RESULTS
Figure 2 outlines the process used to select eligible HTAs for
the review. We identified test evaluations for eighty-nine clini-
cal indications in thirty-one eligible HTA reports. Testing was
reported as being undertaken for diagnostic purposes (62 per-
cent), staging (27 percent), and for screening (6 percent). Four
percent of tests were classified as both diagnostic and staging,
while 1 percent were jointly diagnostic and therapeutic.
Of the eighty-nine test evaluations, 96 percent used either
an abridged (where evidence is linked through to management
changes but not patient outcomes) or full LEA methodology,
with 61 percent undertaking the full linkage. Overall, 35 per-
cent of test evaluations were reported as not requiring a full
linkage of evidence. This was usually because the test did not
identify patients with a different spectrum of disease (i.e., dif-
ferent marker or stage of disease) and, as treatment effectiveness
was already well known in that patient population, evidence of
the impact of treatment did not need to be re-evaluated. The pro-
portion of abridged LEA evaluations increased from 19 percent
in 2007 to 47–50 percent 2 to 3 years later.
In 25 percent (22/89) of the test evaluations, the HTA au-
thors reported difficulties with methodology. These difficul-
ties all involved the use of an abridged or full LEA. None of
these evaluations involved the 4 percent of HTAs that used
an approach that synthesized direct evidence alone. In the
“problematic” HTAs using LEA, five main challenges were
identified.
1. Imperfect reference standard: In 34 percent of cases
where there was not enough information to determine test ac-
curacy, problems in applying LEA were reported. Test accuracy
could not be determined because there were insufficient or only
low quality studies available or the reference standard was im-
perfect. Where evidence was lacking, most HTA authors did not
report a fault with the LEA approach, they simply reported that
the evidence-base was limited. However, when problems with
345 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 29:3, 2013
Merlin et al.
Potenally relevant reports screened 
for retrieval: k=72 
Reports retrieved for more detailed 
evaluaon: k=66 
Reports excluded: 
 Report withdrawn or not 
produced – k=4 
 Report is commercial-in-
conﬁdence – k=2 
Reports excluded: 
 Not a test – k=30 
Potenally appropriate reports to be 
included in the systemac review: 
k=36; clinical indicaons for test use: 
n=100 Reports excluded: 
 Test for monitoring only – 
k=3 
 Duplicate report – k=2 
Reports included in the systemac 
review:  k=31;  

















Eligible HTA reports listed on MSAC 
Web site Aug 2005-Mar 2012: 
Referrals: k=18 








excluded:  n=11 
Figure 2. PRISMA flowchart. Adapted from Liberati et al. (2009).
LEA were reported (N = 22), 41 percent of the problems iden-
tified involved an imperfect reference standard against which
test accuracy (the first component of the linkage) was bench-
marked. These includedHTAs on optical coherence tomography
(13) and molecular testing for myeloproliferative disease (14).
2. Spectrum of disease differences: When the new test was
more accurate than the designated comparator, inability to as-
sess likely treatment effectiveness in test positive patients was
a frequently reported difficulty (18 percent; N = 22). Current
treatment options would have only been trialed in populations
with a spectrum of disease identified by the less accurate com-
parator test. Overall, 33 percent (N= 15) of HTAs of highly sen-
sitive and specific tests reported difficulties using LEA. These
included positron emission tomography for staging cervical can-
cer (15), and magnetic resonance imaging for breast cancer
screening in high risk women (16).
3. “Rule out” tests: Determining probable health benefits in
symptomatic patients that are ruled out from the target condition
can also be difficult using LEA. Evidence cannot practically be
obtained on the myriad of treatment options that may be offered
a patient testing negative. Perhaps they receive an early and
accurate differential diagnosis to explain their symptoms or, if
triage tested, avoid further unnecessary, and potentially inva-
sive, testing. Approximately half (43 percent) of the handful of
HTAs of “rule out” tests (N = 7) reported difficulties applying
LEA. Example HTAs where this problem was reported include
brain natriuretic peptide testing to rule out heart failure (17) and
positron emission tomography to rule out glioma (18). In the
remaining HTAs of this test type there was insufficient infor-
mation to fully complete the evidence linkage, that is, there was
no apparent change in patient management as a consequence
of the test or the data were insufficient to come to any conclu-
sions regarding a change in management. Therefore, problems
that would normally be faced when addressing the third linkage
(impact on patient health outcomes) did not eventuate.
4. Established tests: Medical tests that are already in estab-
lished practice but have not previously received public funding
were considered difficult to assess. In this situation, nominat-
ing the appropriate comparator test strategy was reported as
the main difficulty. This issue was reported in HTAs of urinary
metabolic profiling for the detection ofmetabolic disorders (19).
5. Surrogate outcomes: Evaluating the clinical impact of
tests when the evidence was limited to surrogate outcomes was
reported as an issue. Additional information would be required
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Figure 3. Decision framework to implement the linked evidence approach when evaluating medical tests.
in the linkage to address the validity of the surrogate outcome.
For example, hepatitis B virus (HBV) DNA testing and the use
of serum HBV DNA levels as a surrogate for clinical outcomes
(20) would require, in the absence of direct evidence, informa-
tion on the prognostic value of serum HBV DNA levels.
No problems were identified using LEA for “rule in” tests.
Development of a Decision Framework to Apply LEA
A decision framework was developed to help guide the imple-
mentation of LEA (Figure 3). This framework was developed
on the basis of information obtained on LEA during the system-
atic review, most notably the increasing use of abridged LEA,
indicating that evaluators are applying their own “rules” when
using a linked evidence approach. The framework incorporates
three scenarios:
A. Optimization: In this scenario, if the test is found to be
as accurate as the comparator test but not as safe, the result is
a net harm; any additional evidence to inform the policy maker
(including cost information) is likely to be superfluous. Con-
versely, an assessment of the impact of the new test on patient
management is recommended when safety is not a concern as
decision makers will be interested in whether the test has any
advantages over its comparator in terms of usage (and thus cost
implications). As the spectrum of disease in patients receiving
these tests is unlikely to differ from that in the existing treated
population (given test accuracy is similar), a review of treatment
effectiveness would not be required as the treatment options are
unlikely to change. At best, if there are safety or accessibility
benefits with the new test, the management and treatment of
tested patients will be optimized.
B. Trade-off: When the test being assessed is less accurate
than the comparator test, then an assessment of test invasiveness
or safety is needed to determine whether there is a net harm or a
trade-off in safety and test performance. The trade-off analysis
will need to determine the consequences of treating or not treat-
ing, respectively, the likely increase in false-positive (FP) or
false-negative (FN) diagnoses. Treatment options for patients
with a true-positive (TP) or true-negative (TN) diagnosis are
unlikely to change as a consequence of the test and so do not
need assessment.
When it is impossible to determine test accuracy (e.g., im-
perfect reference standard) a conservative approach is needed
to determine all the possible consequences of testing. The im-
plications of false negatives and positives need to be explored,
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as well as, conversely, the potential to uncover a spectrum of
disease for which the natural history (and, therefore, impact of
treatment) is largely unknown (see scenario C below). Sequen-
tial linkages of evidence are required to build a picture of the
overall clinical effectiveness of the test.With each linkage in the
synthesis, the uncertainty regarding the transferability between
linkages is increased.
C. Disease spectrum change: Of all the scenarios, the one
where a randomized controlled trial is most needed is when the
new test proves to be more accurate than the comparator test.
In the absence of direct evidence, the consequences of treat-
ment, or avoidance of treatment, in all patients receiving a more
accurate test are difficult to determine because the absolute ben-
efit of the treatment in the new cases detected is not likely to be
known. This benefit is likely to depend on the patient prognosis
without the treatment, as well as the comparative effectiveness
and risks of the treatment in these particular patients (7).
If the test is more accurate but less safe than the comparator
test, there is a trade-off situation and a cost-effectiveness analy-
sis is likely to be warranted. If the test has similar safety it may
be used as an additional test for patients testing negative on the
comparator. If the test has better performance and safety, then
a cost-effectiveness analysis may be performed to determine
whether it is a suitable replacement for the comparator.
If the test is more sensitive, prognostic or clinical evidence
is needed to determine treatment effectiveness in patients diag-
nosed with the new test. Evidence is also needed on the impact
of early versus delayed treatment to determine if there are ben-
efits associated with the reduction in false negatives. If the test
is more specific, prognostic or clinical evidence is needed to
determine if there are better health outcomes in true negatives.
Evidence is also needed on the consequences of inappropriate
treatment of false positives to determine if there are benefits
associated with the reduction in false positives. As noted in
scenario B, with each linkage in the synthesis, the uncertainty
regarding the transferability between linkages increases.
DISCUSSION
Feasibility of LEA
In most cases where direct evidence of a medical test’s impact
on patient health outcomes is limited or lacking, LEA can pro-
vide a transparent evidence synthesis to inform public funding
decisions regarding the clinical effectiveness of the test. Fur-
thermore, because the data have been systematically acquired,
it can then be used as inputs in the decision analytic modeling
underpinning an economic analysis, leading to arguably less
biased representation of inputs and transition probabilities in
economic models (21).
However, there are some situations where the LEA synthe-
sis may mislead policy makers as to the clinical effectiveness of
the test, either because insufficient information is presented to
address areas of uncertainty or because these uncertainties have
not been explicated. Some of these situations were anticipated
by the MSAC diagnostic guidelines (6); namely, that LEA may
be inadequate to act as a proxy for direct evidence in instances
where there are spectrum of disease differences between the
tested population and the treated population (i.e., the test iden-
tifies new cases that cannot be identifiedwith existing tests); and
where there is an imperfect reference standard against which to
determine test accuracy.
We have identified two circumstances where evidence addi-
tional to the standard LEA synthesis is considered necessary: (i)
“rule out” tests, and (ii) when evidence only reports on surrogate
outcomes.
Currently, the traditional linked evidence approach is based
on the assumption that the test predicts the disease and that
this will impact on the health of patients with that disease. The
framework does not take into account the benefits or harms from
being “ruled out” from the disease and/or investigated for a dif-
ferent condition, as would occur with direct evidence. Health
outcomes in test-treatment trials are captured for all patients
who test positive and negative for the condition in both the new
test and existing test trial arms (Figure 1). This is of particular
relevance to triage testing as the benefits of a triage test often
reside in those patients “ruled out” from the diagnosis, through
not having unnecessary, usually invasive, “gold standard” test-
ing and/or earlier differential diagnosis and management of the
cause of their symptoms (22). Inability to measure the health
benefits from being ruled out can be particularly critical when
assessing the cost-effectiveness of a triage test. It is important
that some attempt is made to identify if there are any health ben-
efits from “ruling out” symptomatic patients from a condition
through use of the test.
This is not a concern in a “well” or screening population that
is receiving the triage test. Those that are “ruled out” (assuming
the test has a low false-negative rate) are simply confirmed
as healthy. They do not need to be investigated for alternative
diagnoses and so treatment effectiveness in the “ruled out” arm
is not an issue. In a screening population, the main issue is false-
positive and true-positive diagnoses and these factors would be
considered under LEA.
In instances where an HTA reports spectrum of disease
differences between tested and treated populations, or when
outcomes reported in the evidence base are surrogates for clini-
cal endpoints, it has been suggested that additional information
is provided to address likely patient prognosis following treat-
ment in the tested population. This could take the form of, re-
spectively, a short-term randomized controlled trial comparing
treatment outcomes in those receiving the new test versus the
comparator test (7), or observational evidence demonstrating an
association between the surrogate outcome and patient-relevant
clinical outcomes (23).
When undertaking an HTA of an established test, LEA was
reported as challenging because of the difficulty in identifying
the relevant comparator test. This problem arises simply because
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 29:3, 2013 348
Analysis of the linked evidence approach
the evidence base (whether “direct” or LEA) assumes that the
established test is the benchmark and thus it is either incorpo-
rated in the comparator or the only available comparators are
new/unassessed tests. In these cases, historical comparatorsmay
be used (e.g., by assuming a scenario where the test was never
established) (14) or surveillance of clinical outcomes in patients
receiving the established test could be used to supplement the
linkage.
Decision Framework to Apply LEA
The draft methods guide, released by the Agency for Health-
care Research and Quality (AHRQ) (1), suggests that analytic
frameworks (9) and/or decision trees and flow charts should be
created as a matter of principle when reviewing medical tests.
Complementary to this approach, Lord et al suggest using the
principles of randomized controlled trial design as a hypothet-
ical framework to identify what types of comparative evidence
are required to evaluate medical tests (7).
These frameworks for evaluating medical tests rightly sug-
gest that all relevant areas of evidence-based enquiry should be
mapped out before collating and selecting evidence. However,
little attention is given as to whether it is still relevant to pursue
the planned synthesis once there are findings that negate the
need to continue with the linkage.
Our review of MSAC HTAs, although potentially limited
by duplicate data extraction of only half of the assessments,
found that over time there was a reduction in the proportion of
evidence syntheses that undertook a full linkage of evidence. In
later years, only approximately half reported that a full linkage
was either possible or warranted. No formal decision frame-
work was presented to justify this abridged linkage, although
the logic for truncating the synthesis was invariably provided.
These abridged linkages may have increased over time as a con-
sequence of growing familiarity with LEA by the HTA evalu-
ation groups or the evidence may just not have been available
to proceed with a full linkage and so the LEA was truncated by
necessity.
On the basis of these observations, we have proposed a
formal decision framework for applying LEA. The framework
isBayesian in that prior information affects subsequent evidence
synthesis decisions. Although the work is limited to Australian
HTAs, the identified benefits and limitationswith LEA are likely
to be broadly applicable to any HTA of medical tests; although,
this would need to be tested.
Policy Implications of this Research
Medical tests are complex interventions, simply because of
the downstream consequences associated with testing. General
methods for dealing with complex interventions have been pro-
posed (24), as well as methods specific to medical tests (1;7).
These include conceptualizing a priori the overall theoretical
basis for linking evidence (7), as well as the optimal study de-
signs needed to address or measure assumptions inherent in the
synthesis plan (8).
Where this study differs from previous research is by
proposing that any a priori conceptualization of questions rel-
evant to an evidence synthesis for a medical test should subse-
quently be tailored according to the evidence that is found. We
have formulated a framework that recognizes the necessary pre-
conditions for determining the clinical effectiveness of a test.
When these conditions are not met, it is wasteful of resources
and potentially confusing to policy makers to proceed with the
collation of evidence as outlined in the synthesis plan.
These preconditions appear to have been informally imple-
mented, to a greater or lesser extent, with growing frequency in
recent Australian HTAs. The decision framework we have pro-
posed incorporates the lessons learned with LEA, and aims to
facilitate transparency and standardized use of themethodology.
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